Matthew Meyerson
Vice President for Healthcare Outcomes Policy and
Oncology and Molecular Radiation Sciences
Biotools Inc
Norway
Biography
Matthew Meyerson, MD, PhD, has been appointed the Institute's first director of Cancer Genomics.In this new position, Meyerson, a Dana-Farber and Harvard faculty member since 1998, will be responsible for advancing basic, translational, and clinical research in cancer genomics, both at the Institute and in partnership with researchers at Brigham and Women's Hospital (BWH), Boston Children's Hospital (BCH), and the Broad Institute of MIT and Harvard, where Meyerson is an Institute member. Meyerson is also being named director of Cancer Genomics at the Broad.
Research Interest
Dana-Farber and its collaborating institutions to forge one of the world's leading research programs in patient-centered cancer genomics. "Cancer genomics is undergoing a technology revolution," he observes. "Thanks to these advances, genomics exerts an ever-increasing impact on cancer diagnosis and treatment. Dana-Farber Cancer Institute is poised to make great strides as a leader in cancer genomics, to benefit our cancer patients here in Boston, and throughout the United States."
